Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project
Amanda Katherina Herbrand, Andreas Michael Schmitt, Matthias Briel, Stefan Diem, Hannah Ewald, Anouk Hoogkamer, Markus Joerger, Kimberly Alba Mc Cord, Urban Novak, Sirintip Sricharoenchai, Lars G Hemkens & Benjamin Kasenda
Our study will provide a systematic overview and assessment of OLU and its reimbursement reality in Switzerland. We may provide a better understanding of the access to cancer care that is regulated by health insurers and we hope to identify factors that determine the level of evidence-based cancer care in a highly diverse western healthcare system.
|citation||Herbrand A K, Schmitt A M, Briel M, Diem S, Ewald H, Hoogkamer A, Joerger M, Mc Cord K A, Novak U, Sricharoenchai S, Hemkens L G, Kasenda B. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project. ESMO Open 2019; 4:e000596.|
|type||journal paper/review (English)|
|date of publishing||01-12-2019|
|journal title||ESMO Open (4/6)|